TICKERNERD
Menu
AZTAAZTAHealthcare · Medical Instruments & Supplies

AZTA Stock Forecast: Azenta, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$37
+2.49% on the day

The 6 Wall Street analysts covering Azenta, Inc. hold a median 12-month price target of $35 — -6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 22 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$1.6B
Ticker Nerd rank
80 / 100
Median analyst target
$35
Analysts covering
6
Total return, dividends reinvested
1W
+12.1%
1M
+40.7%
YTD
+12.5%
1Y
+25.4%
From 52W high
−8.8%
From 52W low
+133.6%
$16
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AZTA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Azenta, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Value
86
Issuance
83
Quality
75
Volatility
67
Momentum
49
Revisions
48
Growth
44
Size
38

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (44): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (38): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AZTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AZTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26AZTAHigh $37Median $35Low $33

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
3 Buy3 Hold0 Sell
Low $33Median $35High $37

The green dot is the last close — the median target sits −6.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Aug 2026Evercore ISI GroupMaintainsOutperform$28 → $35
5 Aug 2026NeedhamMaintainsBuy$33 → $37
6 May 2026NeedhamMaintainsBuy$44 → $33
6 May 2026NeedhamMaintainsBuy—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
17 Mar 2026NeedhamReiteratesBuy—
5 Feb 2026Evercore ISI GroupMaintainsOutperform—
4 Feb 2026JefferiesMaintainsBuy—
4 Feb 2026NeedhamReiteratesBuy—
8 Jan 2026TD CowenMaintainsHold—
5 Jan 2026Evercore ISI GroupUpgradeOutperform—
19 Dec 2025NeedhamMaintainsBuy—
25 Nov 2025Raymond JamesMaintainsOutperform—
21 Nov 2025NeedhamMaintainsBuy—
30 Oct 2025JefferiesUpgradeBuy—
6 Aug 2025Raymond JamesUpgradeOutperform—
5 Aug 2025Evercore ISI GroupMaintainsIn-Line—
8 July 2025Evercore ISI GroupMaintainsIn-Line—
7 May 2025NeedhamMaintainsBuy—
6 Feb 2025Evercore ISI GroupMaintainsIn-Line—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AZTA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AZTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−20.3%
Analysts raising
2
Analysts cutting
2
Fundamentals

Azenta, Inc. (AZTA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
31.7×

Cheaper than 25% of US stocks

Price / sales
2.7×

Cheaper than 46% of US stocks

Price / book
1.1×

Cheaper than 71% of US stocks

EV / EBITDA
40.2×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
12.0%

Higher than 57% of US stocks

Earnings growth (YoY)
12.0%

Higher than 50% of US stocks

Gross margin
44.9%

Higher than 56% of US stocks

Operating margin
−2.3%

Higher than 30% of US stocks

Net margin
−20.0%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−7.0%

Higher than 38% of US stocks

Return on assets
−0.7%

Higher than 40% of US stocks

Dividend yield
1.1%

Higher than 25% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AZTA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
AZTAAzenta, Inc.$1.6B
80
BLFSBioLife Solutions, Inc.$1.8B
91
LMATLeMaitre Vascular, Inc.$1.9B
75
KMTSKestra Medical Technologies Ltd.$1.6B
21
XRAYDentsply Sirona, Inc.$2.2B
91
ATRCAtriCure, Inc.$2.5B
94
STAASTAAR Surgical Co.$1.2B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Azenta, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AZTA news & analysis

Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue

Seeking Alpha · 14 Aug 2026neutral

Azenta shares, which hit a multi-year low in May 2026, have since doubled in value, but the article warns that a chart pattern suggests the rally could unwind in the near future. The current financial model supports being long, but that depends on Azenta hitting the targets it has laid out.

Why it matters — A Azenta watcher would care because the piece highlights that the recent sharp rally may not be sustainable and that the stock's outlook hinges on the company meeting its stated financial targets.

Azenta, Inc. (AZTA) Q3 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Azenta, Inc. published the transcript of its Q3 2026 earnings call, as covered by Seeking Alpha. The transcript contains management's discussion from the earnings call.

Why it matters — An AZTA watcher would care because the transcript provides direct insight into management's earnings commentary and discussion of the quarter.

Azenta Q3 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Azenta reported third-quarter fiscal 2026 revenue above its outlook, driven by growth in recurring-revenue businesses and improved Multiomics performance, which helped offset ongoing unevenness in capital equipment markets.

Why it matters — The revenue beat suggests that Azenta's strategic shift toward recurring-revenue streams and its Multiomics segment are gaining traction, which could support more stable financial performance going forward.

Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.

PRNewsWire · 4 Aug 2026neutral

Azenta, Inc. (Nasdaq: AZTA) announced its financial results for the third quarter of fiscal 2026, which ended June 30, 2026. The results were reported in a press release issued on August 4, 2026, from Burlington, Massachusetts.

Why it matters — A quarterly financial report is a scheduled disclosure that gives Azenta watchers insight into the company's recent performance and fiscal trajectory.

FAQ

Frequently asked questions about AZTA stock

What is the AZTA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Azenta, Inc. have a median 12-month price target of $35, with estimates ranging from $33 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AZTA stock a buy right now?

Of the 6 analysts covering Azenta, Inc., 3 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Azenta, Inc. 80 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AZTA?

As at 22 Aug 2026, Azenta, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will AZTA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies -6.5% from the last close, and Ticker Nerd's factor model ranks Azenta, Inc. 80 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AZTA stock forecast for 2030?

No analyst covering Azenta, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AZTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $33 to $37 over the next 12 months.

How has AZTA stock performed over the past year?

Azenta, Inc. returned +25.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Azenta, Inc. do?

Azenta, Inc. is a provider of life sciences solutions specializing in cold-chain sample management and multiomics services for pharmaceutical, biotechnology, academic, and healthcare institutions worldwide.

What is the latest news on AZTA?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue". Azenta shares, which hit a multi-year low in May 2026, have since doubled in value, but the article warns that a chart pattern suggests the rally could unwind in the near future. The current financial model supports being long, but that depends on Azenta hitting the targets it has laid out.

Company

About Azenta, Inc.

Azenta, Inc. is a provider of life sciences solutions specializing in cold-chain sample management and multiomics services for pharmaceutical, biotechnology, academic, and healthcare institutions worldwide. The company operates through two primary segments: Sample Management Solutions, which offers automated storage systems, cryogenic equipment, sample tubes, consumables, instruments, controlled-rate thawing devices, and biorepository services to ensure the secure handling and long-term preservation of biological and chemical samples; and Multiomics, which delivers genomic analysis including next-generation sequencing and gene synthesis through its GENEWIZ brand. Azenta supports drug development, clinical research, and advanced cell therapies by maintaining sample integrity via its global biorepository network and providing essential infrastructure for precision medicine initiatives. Notable brands under Azenta include FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey, covering sample management tools, informatics, and cold-chain technologies. With operations across North America, Europe, and Asia, and headquartered in Burlington, Massachusetts, Azenta plays a critical role in the life sciences ecosystem by enabling efficient workflows for high-impact research and development programs.

CEO Mr. John P. Marotta · 2,900 employees · United States · https://www.azenta.com